<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616354</url>
  </required_header>
  <id_info>
    <org_study_id>Two-step Dosing Of Imipenem</org_study_id>
    <nct_id>NCT02616354</nct_id>
  </id_info>
  <brief_title>Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin</brief_title>
  <acronym>PROTDOI</acronym>
  <official_title>Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Explore Imipenem/Cilastatin two-step dosing compared to 2 hours infusion in patients with
      severe whether can obtain better results of the pharmacokinetic/pharmacodynamic, for clinical
      rational use of antimicrobial agents, and provide theoretical support for optimizing dosage
      regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compared with Imipenem/Cilastatin 2 hours continuous dosing method and two-step dosing method
      (0.5 hours before enter half dose, after 1.5 hours, the other half of the input dose) of
      blood drug concentration in the body than the minimal inhibitory concentrations (MIC)
      pathogens percent of dosing interval duration (100% fT &gt; MIC), blood drug concentration in
      the body more than 4 times the minimal inhibitory concentrations (MIC) pathogens percent of
      dosing interval duration (100% fT &gt; 4 MIC), blood drug concentration peak and the ratio of
      the minimal inhibitory concentrations (MIC) pathogens (Cmax/MIC), blood drug concentration
      (Tmax) used in the peak time, used to guide clinical patients with severe infection of
      Imipenem/Cilastatin usage.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>up to 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration</measure>
    <time_frame>up to 9 months</time_frame>
    <description>immediately prior to imipenem/cilastatin administration (time 0 min) and at 30 min, 1h, 2h, 4h, 6h and 8h after administration of the infusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PK/PD indices</measure>
    <time_frame>up to 9 moths</time_frame>
    <description>Time&gt;MIC (∫T&gt;MIC) and 4×MIC (∫T&gt;4×MIC)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group I received intravenous imipenem/cilastatin 1 g every 8 h (q8h) or 0.5g every 6 h (q6h) with optimized two-step infusion therapy (OTIT; rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours) &quot;Group I&quot; is more informative than &quot;Group II&quot; from PK parameters(%T&gt;MIC,AUC/MIC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>group II received intravenous imipenem/cilastatin 1g q8h or 0.5g q6h with extended infusion therapy (2-hours continuous infusion in a constant speed).
&quot;Group I&quot; is more informative than &quot;Group II&quot; from PK parameters(%T&gt;MIC,AUC/MIC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem</intervention_name>
    <description>Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <other_name>Optimized two-step infusion therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sepsis or severe sepsis or severe infections in the previous 48 hours

          -  treatment with imipenem/cilastatin (recommended by hospital microbiologists)

          -  expected duration of hospital stays in the ICU ≥ 72 h from recruitment

          -  recruited patients agreed to participate in this trial, and had set up a signed
             informed consent

        Exclusion Criteria:

          -  with an allergy to carbapenems or with an adverse drug reaction to imipenem

          -  acute or chronic renal failure assessed by serum creatinine concentrations &gt; 280
             μmol/L (or creatinine clearance &lt;20mL/min) or those requiring continuous renal
             replacement therapy

          -  drug or alcohol abuse

          -  Pregnant and lactant women

          -  patients near to death
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kang Xu, master</last_name>
    <phone>+8615851836872</phone>
    <email>xukangyc@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kang Xu</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang Xu</last_name>
      <phone>+86 15851836872</phone>
      <email>xukangyc@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Jianfeng Xie</investigator_full_name>
    <investigator_title>Deputy director of the physician</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics; pharmacodynamic; imipenem; sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

